Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Efficacy of Neoadjuvant Therapy in Improving Long-Term Survival of Patients with Resectable Rectal Cancer: A Meta-Analysis

Author(s): Xinlong Li, Xiangyuan Li, Rongrong Fu, Derry Ng, Tong Yang, Yu Zhang, Mengting Zhang, Yetan Shi, Yixuan Gu, Chenhui Lv and Gang Chen *

Volume 22, Issue 6, 2022

Published on: 26 July, 2021

Page: [1068 - 1079] Pages: 12

DOI: 10.2174/1871520621666210726134809

Price: $65

Abstract

Background: The impact of neoadjuvant therapy on long-term prognosis of patients with resectable rectal cancer is currently unknown.

Objective: This study aimed to explore the long-term prognosis of patients with resectable rectal cancer following treatment with neoadjuvant therapy.

Methods: Four major databases (PubMed, Web of Science, Embase, Cochrane library) were searched to identify relevant articles published between January 2000 and July 2020. The main outcome indicators were the 5-year Overall Survival (OS) and Disease-Free Survival (DFS).

Results: The meta-analysis revealed that 5-year OS (HR: 0.88, 95% Cl: 0.83-0.93) and DFS (HR: 0.95, 95% Cl: 0.91- 0.98) were higher in patients with resectable rectal cancer after receiving neoadjuvant therapy than those treated with upfront surgery. Subgroup analysis demonstrated that the long-term survival of patients in Asia and Europe could benefit from neoadjuvant therapy. The neoadjuvant short-course radiotherapy (SCRT) and neoadjuvant chemoradiotherapy (CRT) improved the 5-year OS and DFS of patients with stage II-III rectal cancer and mid/low rectal cancer. Further research found that patients with stage II only had an increase in OS, while patients with stage Ⅲ have improved 5-year OS and DFS.

Conclusion: Neoadjuvant therapy improved the long-term survival of patients with mid/low rectal cancer in stage Ⅱ-Ⅲ (especially stage Ⅲ). Additionally, patients in Asia and Europe seemed to be more likely to benefit from neoadjuvant therapy. For the treatment, we recommend neoadjuvant SCRT and neoadjuvant CRT for resectable rectal cancer.

Keywords: Rectal neoplasms, neoplasms, neoadjuvant therapy, disease-free survival, survival rate, meta-analysis.

« Previous Next »
Graphical Abstract

[1]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Downing, A.; Glaser, A.W.; Finan, P.J.; Wright, P.; Thomas, J.D.; Gilbert, A.; Corner, J.; Richards, M.; Morris, E.J.A.; Sebag-Montefiore, D. Functional outcomes and health-related quality of life after curative treatment for rectal cancer: A population-level study in england. Int. J. Radiat. Oncol. Biol. Phys., 2019, 103(5), 1132-1142.
[http://dx.doi.org/10.1016/j.ijrobp.2018.12.005] [PMID: 30553942]
[3]
Eid, Y.; Bouvier, V.; Menahem, B.; Thobie, A.; Dolet, N.; Finochi, M.; Renier, M.; Gardy, J.; Launoy, G.; Dejardin, O.; Morello, R.; Alves, A. Digestive and genitourinary sequelae in rectal cancer survivors and their impact on health-related quality of life: Outcome of a high-resolution population-based study. Surgery, 2019, 166(3), 327-335.
[http://dx.doi.org/10.1016/j.surg.2019.04.007] [PMID: 31204071]
[4]
Glynne-Jones, R; Wyrwicz, L; Tiret, E; Brown, G; Rödel, C Cervantes, A Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017. 28(suppl_4), iv22-iv40.
[5]
Folkesson, J.; Birgisson, H.; Pahlman, L.; Cedermark, B.; Glimelius, B.; Gunnarsson, U. Swedish rectal cancer trial: Long lasting benefits from radiotherapy on survival and local recurrence rate. J. Clin. Oncol., 2005, 23(24), 5644-5650.
[http://dx.doi.org/10.1200/JCO.2005.08.144] [PMID: 16110023]
[6]
Peeters, K.C.M.J.; Marijnen, C.A.M.; Nagtegaal, I.D.; Kranenbarg, E.K.; Putter, H.; Wiggers, T.; Rutten, H.; Pahlman, L.; Glimelius, B.; Leer, J.W.; van de Velde, C.J. The TME trial after a median follow-up of 6 years: Increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann. Surg., 2007, 246(5), 693-701.
[http://dx.doi.org/10.1097/01.sla.0000257358.56863.ce] [PMID: 17968156]
[7]
Sebag-Montefiore, D.; Stephens, R.J.; Steele, R.; Monson, J.; Grieve, R.; Khanna, S.; Quirke, P.; Couture, J.; de Metz, C.; Myint, A.S.; Bessell, E.; Griffiths, G.; Thompson, L.C.; Parmar, M. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicentre, randomised trial. Lancet, 2009, 373(9666), 811-820.
[http://dx.doi.org/10.1016/S0140-6736(09)60484-0] [PMID: 19269519]
[8]
Abraha, I.; Aristei, C.; Palumbo, I.; Lupattelli, M.; Trastulli, S.; Cirocchi, R.; De Florio, R.; Valentini, V. Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma. Cochrane Database Syst. Rev., 2018, 10(10), CD002102.
[http://dx.doi.org/10.1002/14651858.CD002102.pub3] [PMID: 30284239]
[9]
Ammann, K.; Kirchmayr, W.; Klaus, A.; Mühlmann, G.; Kafka, R.; Oberwalder, M.; De Vries, A.; Ofner, D.; Weiss, H. Impact of neoadjuvant chemoradiation on anal sphincter function in patients with carcinoma of the midrectum and low rectum. Arch. Surg., 2003, 138(3), 257-261.
[http://dx.doi.org/10.1001/archsurg.138.3.257] [PMID: 12611569]
[10]
Gérard, J-P.; Conroy, T.; Bonnetain, F.; Bouché, O.; Chapet, O.; Closon-Dejardin, M-T.; Untereiner, M.; Leduc, B.; Francois, E.; Maurel, J.; Seitz, J.F.; Buecher, B.; Mackiewicz, R.; Ducreux, M.; Bedenne, L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J. Clin. Oncol., 2006, 24(28), 4620-4625.
[http://dx.doi.org/10.1200/JCO.2006.06.7629] [PMID: 17008704]
[11]
Minsky, B.D.; Cohen, A.M.; Enker, W.E.; Saltz, L.; Guillem, J.G.; Paty, P.B.; Kelsen, D.P.; Kemeny, N.; Ilson, D.; Bass, J.; Conti, J. Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Int. J. Radiat. Oncol. Biol. Phys., 1997, 37(2), 289-295.
[http://dx.doi.org/10.1016/S0360-3016(96)00487-7] [PMID: 9069299]
[12]
Fokas, E.; Liersch, T.; Fietkau, R.; Hohenberger, W.; Beissbarth, T.; Hess, C.; Becker, H.; Ghadimi, M.; Mrak, K.; Merkel, S.; Raab, H.R.; Sauer, R.; Wittekind, C.; Rödel, C. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: Updated results of the CAO/ARO/AIO-94 trial. J. Clin. Oncol., 2014, 32(15), 1554-1562.
[http://dx.doi.org/10.1200/JCO.2013.54.3769] [PMID: 24752056]
[13]
Sauer, R.; Liersch, T.; Merkel, S.; Fietkau, R.; Hohenberger, W.; Hess, C.; Becker, H.; Raab, H.R.; Villanueva, M.T.; Witzigmann, H.; Wittekind, C.; Beissbarth, T.; Rödel, C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J. Clin. Oncol., 2012, 30(16), 1926-1933.
[http://dx.doi.org/10.1200/JCO.2011.40.1836] [PMID: 22529255]
[14]
Lin, J.; Peng, J.; Qdaisat, A.; Li, L.; Chen, G.; Lu, Z.; Wu, X.; Gao, Y.; Zeng, Z.; Ding, P.; Pan, Z. Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer. J. Cancer Res. Clin. Oncol., 2016, 142(12), 2551-2560.
[http://dx.doi.org/10.1007/s00432-016-2225-1] [PMID: 27613188]
[15]
Clancy, C.; Flanagan, M.; Marinello, F.; O’Neill, B.D.; McNamara, D.; Burke, J.P. Comparative oncologic outcomes of upper third rectal cancers: A meta-analysis. Clin. Colorectal Cancer, 2019, 18(4), e361-e367.
[http://dx.doi.org/10.1016/j.clcc.2019.07.004] [PMID: 31445919]
[16]
Fleming, F.J.; Påhlman, L.; Monson, J.R.T. Neoadjuvant therapy in rectal cancer. Dis. Colon Rectum, 2011, 54(7), 901-912.
[http://dx.doi.org/10.1007/DCR.0b013e31820eeb37] [PMID: 21654259]
[17]
Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.A.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ, 2009, 339, b2700.
[http://dx.doi.org/10.1136/bmj.b2700] [PMID: 19622552]
[18]
Allaix, M.E.; Arezzo, A.; Giraudo, G.; Morino, M. Transanal endoscopic microsurgery vs. laparoscopic total mesorectal excision for T2N0 rectal cancer. J. Gastrointest. Surg., 2012, 16(12), 2280-2287.
[http://dx.doi.org/10.1007/s11605-012-2046-8] [PMID: 23070621]
[19]
Bębenek, M.; Tupikowski, W.; Cisarż, K.; Balcerzak, A.; Wojciechowski, L.; Stankowska, A.; Tarkowski, R. Preoperative treatment does not improve the therapeutic results of abdominosacral amputation of the rectum. World J. Surg., 2012, 36(7), 1686-1692.
[http://dx.doi.org/10.1007/s00268-012-1527-y] [PMID: 22411086]
[20]
Cheung, H.Y.S.; Chung, C.C.; Wong, J.C.H.; Yau, K.K.K.; Li, M.K.W. Laparoscopic rectal cancer surgery with and without neoadjuvant chemo-irradiation: A comparative study. Surg. Endosc., 2009, 23(1), 147-152.
[http://dx.doi.org/10.1007/s00464-008-0081-z] [PMID: 18802735]
[21]
Cho, S.H.; Choi, G-S.; Kim, G.C.; Seo, A.N.; Kim, H.J.; Kim, W.H.; Shin, K.M.; Lee, S.M.; Ryeom, H.; Kim, S.H. Long-term outcomes of surgery alone versus surgery following preoperative chemoradiotherapy for early T3 rectal cancer: A propensity score analysis. Medicine (Baltimore), 2017, 96(12), e6362.
[http://dx.doi.org/10.1097/MD.0000000000006362] [PMID: 28328820]
[22]
de Camargo, M.G.M.; Xhaja, X.; Aiello, A.; Liska, D.; Gorgun, E.; Dietz, D.W.; Kalady, M.F.; Delaney, C.P.; Steele, S.R.; Valente, M.A. Does one size fit all? Risks and benefits of neoadjuvant chemoradiation in patients with clinical stage IIA rectal cancer requiring abdominoperineal resection. Am. J. Surg., 2020, 219(3), 406-410.
[http://dx.doi.org/10.1016/j.amjsurg.2019.10.037] [PMID: 31672306]
[23]
Delaney, C.P.; Lavery, I.C.; Brenner, A.; Hammel, J.; Senagore, A.J.; Noone, R.B.; Fazio, V.W. Preoperative radiotherapy improves survival for patients undergoing total mesorectal excision for stage T3 low rectal cancers. Ann. Surg., 2002, 236(2), 203-207.
[http://dx.doi.org/10.1097/00000658-200208000-00008] [PMID: 12170025]
[24]
den Dulk, M.; Krijnen, P.; Marijnen, C.A.M.; Rutten, H.J.; van de Poll-Franse, L.V.; Putter, H.; Meershoek-Klein Kranenbarg, E.; Jansen-Landheer, M.L.; Coebergh, J.W.; van de Velde, C.J. Improved overall survival for patients with rectal cancer since 1990: The effects of TME surgery and pre-operative radiotherapy. Eur. J. Cancer, 2008, 44(12), 1710-1716.
[http://dx.doi.org/10.1016/j.ejca.2008.05.004] [PMID: 18573654]
[25]
Ferenschild, F.T.J.; Dawson, I.; de Graaf, E.J.R.; de Wilt, J.H.W.; Tetteroo, G.W.M. Preoperative radiotherapy has no value for patients with T2-3, N0 adenocarcinomas of the rectum. Dig. Surg., 2009, 26(4), 291-296.
[http://dx.doi.org/10.1159/000227771] [PMID: 19590212]
[26]
Fucini, C.; Pucciani, F.; Elbetti, C.; Gattai, R.; Russo, A. Preoperative radiochemotherapy in t3 operable low rectal cancers: A gold standard? World J. Surg., 2010, 34(7), 1609-1614.
[http://dx.doi.org/10.1007/s00268-010-0513-5] [PMID: 20213202]
[27]
Han, J.; Noh, G.T.; Yeo, S.A.; Cheong, C.; Cho, M.S.; Hur, H.; Min, B.S.; Lee, K.Y.; Kim, N.K. The number of retrieved lymph nodes needed for accurate staging differs based on the presence of preoperative chemoradiation for rectal cancer. Medicine (Baltimore), 2016, 95(38), e489.1.
[http://dx.doi.org/10.1097/MD.0000000000004891] [PMID: 27661032]
[28]
Huh, J.W.; Jung, E.J.; Park, Y.A.; Lee, K.Y.; Sohn, S-K. Sphincter-preserving operations following preoperative chemoradiation: An alternative to abdominoperineal resection for lower rectal cancer? World J. Surg., 2008, 32(6), 1116-1123.
[http://dx.doi.org/10.1007/s00268-008-9520-1] [PMID: 18330627]
[29]
Hwang, K.; Park, I.J.; Yu, C.S.; Lim, S-B.; Lee, J.L.; Yoon, Y.S.; Kim, C.W.; Kim, J.C. Impression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in rectal cancer. World J. Gastroenterol., 2015, 21(2), 563-570.
[http://dx.doi.org/10.3748/wjg.v21.i2.563] [PMID: 25593475]
[30]
Jawitz, O.K.; Adam, M.A.; Turner, M.C.; Gilmore, B.F.; Migaly, J. Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection. Surgery, 2019, 165(6), 1193-1198.
[http://dx.doi.org/10.1016/j.surg.2019.02.005] [PMID: 30904173]
[31]
Joye, I.; Silversmit, G.; Van Eycken, E.; Debucquoy, A.; Vandendael, T.; Penninckx, F.; Haustermans, K. Survival among clinical stage I-III rectal cancer patients treated with different preoperative treatments: A population-based comparison. Cancer Epidemiol., 2016, 43, 35-41.
[http://dx.doi.org/10.1016/j.canep.2016.06.007] [PMID: 27388565]
[32]
Kao, P-S.; Chang, S-C.; Wang, L-W.; Lee, R-C.; Liang, W-Y.; Lin, T-C.; Chen, W.S.; Jiang, J.K.; Yang, S.H.; Wang, H.S.; Lin, J.K. The impact of preoperative chemoradiotherapy on advanced low rectal cancer. J. Surg. Oncol., 2010, 102(7), 771-777.
[http://dx.doi.org/10.1002/jso.21711] [PMID: 20872811]
[33]
Kulu, Y.; Tarantino, I.; Billeter, A.T.; Diener, M.K.; Schmidt, T.; Büchler, M.W.; Ulrich, A. Comparative outcomes of neoadjuvant treatment prior to total mesorectal excision and total mesorectal excision alone in selected stage ii/iii low and mid rectal cancer. Ann. Surg. Oncol., 2016, 23(1), 106-113.
[http://dx.doi.org/10.1245/s10434-015-4832-5] [PMID: 26305025]
[34]
Lange, M.M.; Martz, J.E.; Ramdeen, B.; Brooks, V.; Boachie-Adjei, K.; van de Velde, C.J.H.; Enker, W.E. Long-term results of rectal cancer surgery with a systematical operative approach. Ann. Surg. Oncol., 2013, 20(6), 1806-1815.
[http://dx.doi.org/10.1245/s10434-012-2832-2] [PMID: 23536052]
[35]
Laurent, C.; Nobili, S.; Rullier, A.; Vendrely, V.; Saric, J.; Rullier, E. Efforts to improve local control in rectal cancer compromise survival by the potential morbidity of optimal mesorectal excision. J. Am. Coll. Surg., 2006, 203(5), 684-691.
[http://dx.doi.org/10.1016/j.jamcollsurg.2006.07.021] [PMID: 17084330]
[36]
Li, Q.; Peng, Y.; Wang, L-A.; Wei, X.; Li, M-X.; Qing, Y.; Xia, W.; Cheng, M.; Zi, D.; Li, C.X.; Wang, D. The influence of neoadjuvant therapy for the prognosis in patients with rectal carcinoma: A retrospective study. Tumour Biol., 2016, 37(3), 3441-3449.
[http://dx.doi.org/10.1007/s13277-015-4153-0] [PMID: 26449827]
[37]
Maas, H.A.A.M.; Lemmens, V.E.P.P.; Nijhuis, P.H.A.; de Hingh, I.H.J.T.; Koning, C.C.E.; Janssen-Heijnen, M.L.G. Benefits and drawbacks of short-course preoperative radiotherapy in rectal cancer patients aged 75 years and older. Eur. J. Surg. Oncol., 2013, 39(10), 1087-1093.
[http://dx.doi.org/10.1016/j.ejso.2013.07.094] [PMID: 23958151]
[38]
Nagasaki, T.; Akiyoshi, T.; Fujimoto, Y.; Konishi, T.; Nagayama, S.; Fukunaga, Y.; Ueno, M. Preoperative chemoradiotherapy might improve the prognosis of patients with locally advanced low rectal cancer and lateral pelvic lymph node metastases. World J. Surg., 2017, 41(3), 876-883.
[http://dx.doi.org/10.1007/s00268-016-3748-y] [PMID: 27730348]
[39]
Rades, D.; Vogelsang, R.P.; Treder, M.; Janssen, S.; Schild, S.E.; Holländer, N.H.; Gögenur, I. A matched-pair study comparing surgery plus neoadjuvant radio-chemotherapy and surgery alone for high rectal cancers. Anticancer Res., 2018, 38(12), 6877-6880.
[http://dx.doi.org/10.21873/anticanres.13063] [PMID: 30504404]
[40]
Räsänen, M.; Renkonen-Sinisalo, L.; Mustonen, H.; Lepistö, A. Is there a need for neoadjuvant short-course radiotherapy in T3 rectal cancer with positive lymph node involvement? A single-center retrospective cohort study. World J. Surg. Oncol., 2019, 17(1), 139.
[http://dx.doi.org/10.1186/s12957-019-1670-0] [PMID: 31395058]
[41]
Read, T.E.; Ogunbiyi, O.A.; Fleshman, J.W.; Birnbaum, E.H.; Fry, R.D.; Myerson, R.J.; Kodner, I.J. Neoadjuvant external beam radiation and proctectomy for adenocarcinoma of the rectum. Dis. Colon Rectum, 2001, 44(12), 1778-1790.
[http://dx.doi.org/10.1007/BF02234455] [PMID: 11742162]
[42]
Saito, N.; Ito, M.; Kobayashi, A.; Nishizawa, Y.; Kojima, M.; Nishizawa, Y.; Sugito, M. Long-term outcomes after intersphincteric resection for low-lying rectal cancer. Ann. Surg. Oncol., 2014, 21(11), 3608-3615.
[http://dx.doi.org/10.1245/s10434-014-3762-y] [PMID: 24923221]
[43]
Shapiro, R.; Ahmed Ali, U.; Lavery, I.C.; Kiran, R.P. Endorectal ultrasound does not reliably identify patients with uT3 rectal cancer who can avoid neoadjuvant chemoradiotherapy. Int. J. Colorectal Dis., 2013, 28(7), 993-1000.
[http://dx.doi.org/10.1007/s00384-013-1645-5] [PMID: 23377857]
[44]
Sineshaw, H.M.; Jemal, A.; Thomas, C.R., Jr; Mitin, T. Changes in treatment patterns for patients with locally advanced rectal cancer in the United States over the past decade: An analysis from the National Cancer Data Base. Cancer, 2016, 122(13), 1996-2003.
[http://dx.doi.org/10.1002/cncr.29993] [PMID: 27074300]
[45]
Sorrentino, L.; Guaglio, M.; Battaglia, L.; Bonfanti, G.; Vitellaro, M.; Bianchi, A.C.; Milione, M.; Belli, F. Neoadjuvant chemo-radiotherapy for cT3N0 rectal cancer: Any benefit over upfront surgery? A propensity score-matched study. Int. J. Colorectal Dis., 2019, 34(12), 2161-2169.
[http://dx.doi.org/10.1007/s00384-019-03446-4] [PMID: 31741026]
[46]
Spitale, A.; Franzetti-Pellanda, A.; Mazzola, P.; Richetti, A.; Mazzuchelli, L.; Bordoni, A. Impact of preoperative radiotherapy on survival in locally advanced rectal cancer: An observational population-based study from the South of Switzerland. Eur. J. Cancer Prev., 2012, 21(2), 139-146.
[http://dx.doi.org/10.1097/CEJ.0b013e32834c9c56] [PMID: 22252302]
[47]
Sprenger, T.; Beißbarth, T.; Sauer, R.; Tschmelitsch, J.; Fietkau, R.; Liersch, T.; Hohenberger, W.; Staib, L.; Gaedcke, J.; Raab, H.R.; Rödel, C.; Ghadimi, M. Long-term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO-94. Br. J. Surg., 2018, 105(11), 1510-1518.
[http://dx.doi.org/10.1002/bjs.10877] [PMID: 29846017]
[48]
Sun, Y.; Lin, H.; Lu, X.; Huang, Y.; Xu, Z.; Huang, S.; Wang, X.; Chi, P. A nomogram to predict distant metastasis after neoadjuvant chemoradiotherapy and radical surgery in patients with locally advanced rectal cancer. J. Surg. Oncol., 2017, 115(4), 462-469.
[http://dx.doi.org/10.1002/jso.24522] [PMID: 28105657]
[49]
Sun, Z.; Adam, M.A.; Kim, J.; Turner, M.C.; Fisher, D.A.; Choudhury, K.R.; Czito, B.G.; Migaly, J.; Mantyh, C.R. Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer. Colorectal Dis., 2017, 19(12), 1058-1066.
[http://dx.doi.org/10.1111/codi.13754] [PMID: 28586509]
[50]
Tabchouri, N.; Eid, Y.; Manceau, G.; Frontali, A.; Lakkis, Z.; Salame, E.; Lecomte, T.; Chapet, S.; Calais, G.; Heyd, B.; Karoui, M.; Alves, A.; Panis, Y.; Ouaissi, M. Neoadjuvant treatment in upper rectal cancer does not improve oncologic outcomes but increases postoperative morbidity. Anticancer Res., 2020, 40(6), 3579-3587.
[http://dx.doi.org/10.21873/anticanres.14348] [PMID: 32487661]
[51]
Tiefenthal, M.; Nilsson, P.J.; Johansson, R.; Glimelius, B.; Påhlman, L. The effects of short-course preoperative irradiation on local recurrence rate and survival in rectal cancer: A population-based nationwide study. Dis. Colon Rectum, 2011, 54(6), 672-680.
[http://dx.doi.org/10.1007/DCR.0b013e318210c067] [PMID: 21552050]
[52]
Tsujinaka, S.; Kawamura, Y.J.; Konishi, F.; Aihara, H.; Maeda, T.; Mizokami, K. Long-term efficacy of preoperative radiotherapy for locally advanced low rectal cancer. Int. J. Colorectal Dis., 2008, 23(1), 67-76.
[http://dx.doi.org/10.1007/s00384-007-0369-9] [PMID: 17704925]
[53]
van Erning, F.N.; Rutten, H.J.T.; van den Berg, H.A.; Lemmens, V.E.P.P.; van Halteren, H.K. Effect of adjuvant chemotherapy on recurrence-free survival varies by neo-adjuvant treatment in patients with stage III rectal cancer. Eur. J. Surg. Oncol., 2015, 41(12), 1630-1635.
[http://dx.doi.org/10.1016/j.ejso.2015.09.011] [PMID: 26437853]
[54]
Wang, F.; Fan, W.; Peng, J.; Lu, Z.; Pan, Z.; Li, L.; Gao, Y.; Li, H.; Chen, G.; Wu, X.; Ding, P.; Zeng, Z.; Wan, D. Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid/low rectal cancer: A long-term analysis of a prospective, single-center, randomized trial. Cancer Commun (Lond), 2018, 38(1), 73.
[http://dx.doi.org/10.1186/s40880-018-0342-8] [PMID: 30572939]
[55]
Watanabe, T.; Tsurita, G.; Muto, T.; Sawada, T.; Sunouchi, K.; Higuchi, Y.; Komuro, Y.; Kanazawa, T.; Iijima, T.; Miyaki, M.; Nagawa, H. Extended lymphadenectomy and preoperative radiotherapy for lower rectal cancers. Surgery, 2002, 132(1), 27-33.
[http://dx.doi.org/10.1067/msy.2002.125357] [PMID: 12110792]
[56]
Williamson, J.S.; Jones, H.G.; Davies, M.; Evans, M.D.; Hatcher, O.; Beynon, J.; Harris, D.A. Outcomes in locally advanced rectal cancer with highly selective preoperative chemoradiotherapy. Br. J. Surg., 2014, 101(10), 1290-1298.
[http://dx.doi.org/10.1002/bjs.9570] [PMID: 24924947]
[57]
Zhan, T.; Gu, J.; Li, M.; Du, C. Intermediate-fraction neoadjuvant radiotherapy for rectal cancer. Dis. Colon Rectum, 2013, 56(4), 422-432.
[http://dx.doi.org/10.1097/DCR.0b013e31828576c6] [PMID: 23478609]
[58]
Zhang, Y.; Sun, Y.; Xu, Z.; Chi, P.; Lu, X. Is neoadjuvant chemoradiotherapy always necessary for mid/high local advanced rectal cancer: A comparative analysis after propensity score matching. Eur. J. Surg. Oncol., 2017, 43(8), 1440-1446.
[http://dx.doi.org/10.1016/j.ejso.2017.04.007] [PMID: 28502421]
[59]
Stoffel, E.M.; Murphy, C.C. Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. Gastroenterology, 2020, 158(2), 341-353.
[http://dx.doi.org/10.1053/j.gastro.2019.07.055] [PMID: 31394082]
[60]
Benson, A.B., III; Venook, A.P.; Bekaii-Saab, T.; Chan, E.; Chen, Y-J.; Cooper, H.S.; Engstrom, P.F.; Enzinger, P.C.; Fenton, M.J.; Fuchs, C.S.; Grem, J.L.; Grothey, A.; Hochster, H.S.; Hunt, S.; Kamel, A.; Kirilcuk, N.; Leong, L.A.; Lin, E.; Messersmith, W.A.; Mulcahy, M.F.; Murphy, J.D.; Nurkin, S.; Rohren, E.; Ryan, D.P.; Saltz, L.; Sharma, S.; Shibata, D.; Skibber, J.M.; Sofocleous, C.T.; Stoffel, E.M.; Stotsky-Himelfarb, E.; Willett, C.G.; Gregory, K.M.; Freedman-Cass, D. Rectal Cancer, Version 2.2015. J. Natl. Compr. Canc. Netw., 2015, 13(6), 719-728.
[http://dx.doi.org/10.6004/jnccn.2015.0087] [PMID: 26085388]
[61]
Lee, N.K.; Kim, C.Y.; Park, Y.J.; Yang, D.S.; Yoon, W.S.; Kim, S.H.; Kim, J. Clinical implication of negative conversion of predicted circumferential resection margin status after preoperative chemoradiotherapy for locally advanced rectal cancer. Eur. J. Radiol., 2014, 83(2), 245-249.
[http://dx.doi.org/10.1016/j.ejrad.2013.10.029] [PMID: 24268789]
[62]
Pettersson, D.; Holm, T.; Iversen, H.; Blomqvist, L.; Glimelius, B.; Martling, A. Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br. J. Surg., 2012, 99(4), 577-583.
[http://dx.doi.org/10.1002/bjs.7796] [PMID: 22241246]
[63]
van Gijn, W.; Marijnen, C.A.; Nagtegaal, I.D.; Kranenbarg, E.M.; Putter, H.; Wiggers, T.; Rutten, H.J.; Påhlman, L.; Glimelius, B.; van de Velde, C.J. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol., 2011, 12(6), 575-582.
[http://dx.doi.org/10.1016/S1470-2045(11)70097-3] [PMID: 21596621]
[64]
Stewart, D.B.; Dietz, D.W. Total mesorectal excision: What are we doing? Clin. Colon Rectal Surg., 2007, 20(3), 190-202.
[http://dx.doi.org/10.1055/s-2007-984863] [PMID: 20011200]
[65]
Nozue, M.; Isaka, N.; Fukao, K. Over-expression of vascular endothelial growth factor after preoperative radiation therapy for rectal cancer. Oncol. Rep., 2001, 8(6), 1247-1249.
[http://dx.doi.org/10.3892/or.8.6.1247] [PMID: 11605042]
[66]
Mongin, C.; Maggiori, L.; Agostini, J.; Ferron, M.; Panis, Y. Does anastomotic leakage impair functional results and quality of life after laparoscopic sphincter-saving total mesorectal excision for rectal cancer? A case-matched study. Int. J. Colorectal Dis., 2014, 29(4), 459-467.
[http://dx.doi.org/10.1007/s00384-014-1833-y] [PMID: 24477790]
[67]
Tevis, S.E.; Kohlnhofer, B.M.; Stringfield, S.; Foley, E.F.; Harms, B.A.; Heise, C.P.; Kennedy, G.D. Postoperative complications in patients with rectal cancer are associated with delays in chemotherapy that lead to worse disease-free and overall survival. Dis. Colon Rectum, 2013, 56(12), 1339-1348.
[http://dx.doi.org/10.1097/DCR.0b013e3182a857eb] [PMID: 24201387]
[68]
Schrag, D.; Weiser, M.; Saltz, L.; Mamon, H.; Gollub, M.; Basch, E.; Venook, A.; Shi, Q. Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance). Clin. Trials, 2019, 16(2), 165-175.
[http://dx.doi.org/10.1177/1740774518824539] [PMID: 30688523]
[69]
Benson, A.B.; Venook, A.P.; Al-Hawary, M.M.; Cederquist, L.; Chen, Y-J.; Ciombor, K.K.; Cohen, S.; Cooper, H.S.; Deming, D.; Engstrom, P.F.; Grem, J.L.; Grothey, A.; Hochster, H.S.; Hoffe, S.; Hunt, S.; Kamel, A.; Kirilcuk, N.; Krishnamurthi, S.; Messersmith, W.A.; Meyerhardt, J.; Mulcahy, M.F.; Murphy, J.D.; Nurkin, S.; Saltz, L.; Sharma, S.; Shibata, D.; Skibber, J.M.; Sofocleous, C.T.; Stoffel, E.M.; Stotsky-Himelfarb, E.; Willett, C.G.; Wuthrick, E.; Gregory, K.M.; Gurski, L.; Freedman-Cass, D.A. Rectal cancer, version 2.2018, nccn clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw., 2018, 16(7), 874-901.
[http://dx.doi.org/10.6004/jnccn.2018.0061] [PMID: 30006429]
[70]
Lee, J.B.; Kim, H.S.; Ham, A.; Chang, J.S.; Shin, S.J.; Beom, S-H.; Koom, W.S.; Kim, T.; Han, Y.D.; Han, D.H.; Hur, H.; Min, B.S.; Lee, K.Y.; Kim, N.K.; Park, Y.R.; Lim, J.S.; Ahn, J.B. Role of preoperative chemoradiotherapy in clinical stage ii/iii rectal cancer patients undergoing total mesorectal excision: A retrospective propensity score analysis. Front. Oncol., 2021, 10, 609313.
[http://dx.doi.org/10.3389/fonc.2020.609313] [PMID: 33537238]
[71]
Zhong, X.; Guo, Z.; Gao, P.; Song, Y.; Sun, J.; Chen, X.; Sun, Y.; Wang, Z. Racial/ethnic disparities in the adjuvant chemotherapy of locally advanced colon cancer patients. J. Surg. Res., 2018, 228, 27-34.
[http://dx.doi.org/10.1016/j.jss.2018.02.054] [PMID: 29907221]
[72]
Iacopetta, B.; Russo, A.; Bazan, V.; Dardanoni, G.; Gebbia, N.; Soussi, T.; Kerr, D.; Elsaleh, H.; Soong, R.; Kandioler, D.; Janschek, E.; Kappel, S.; Lung, M.; Leung, C.S.; Ko, J.M.; Yuen, S.; Ho, J.; Leung, S.Y.; Crapez, E.; Duffour, J.; Ychou, M.; Leahy, D.T.; O’Donoghue, D.P.; Agnese, V.; Cascio, S.; Di Fede, G.; Chieco-Bianchi, L.; Bertorelle, R.; Belluco, C.; Giaretti, W.; Castagnola, P.; Ricevuto, E.; Ficorella, C.; Bosari, S.; Arizzi, C.D.; Miyaki, M.; Onda, M.; Kampman, E.; Diergaarde, B.; Royds, J.; Lothe, R.A.; Diep, C.B.; Meling, G.I.; Ostrowski, J.; Trzeciak, L.; Guzinska-Ustymowicz, K.; Zalewski, B.; Capellá, G.M.; Moreno, V.; Peinado, M.A.; Lönnroth, C.; Lundholm, K.; Sun, X.F.; Jansson, A.; Bouzourene, H.; Hsieh, L.L.; Tang, R.; Smith, D.R.; Allen-Mersh, T.G.; Khan, Z.A.; Shorthouse, A.J.; Silverman, M.L.; Kato, S.; Ishioka, C. Functional categories of TP53 mutation in colorectal cancer: Results of an international collaborative study. Ann. Oncol., 2006, 17(5), 842-847.
[http://dx.doi.org/10.1093/annonc/mdl035] [PMID: 16524972]
[73]
Huang, A.; Xiao, Y.; Peng, C.; Liu, T.; Lin, Z.; Yang, Q.; Zhang, T.; Liu, J.; Ma, H. 53BP1 expression and immunoscore are associated with the efficacy of neoadjuvant chemoradiotherapy for rectal cancer. Strahlenther. Onkol. 2020, 196(5), 465-473.
[http://dx.doi.org/10.1007/s00066-019-01559-x ] [PMID: 31828392]

Rights & Permissions Print Cite
Article Metrics
15
1
© 2024 Bentham Science Publishers | Privacy Policy